The Charles T. Campbell Eye Microbiology Lab
UPMC | University of Pittsburgh Medical CenterUniversity of Pittsburgh Schools of the Health Sciences
HomeAbout UsLab Diagnostic TestingAntibiotic SusceptibilityAntimicrobial TherapyCurrent ResearchContact Us

2010 OMIG, Abstract 10

OMIG Main Page | 2010 Abstracts | < Previous| Next >

In-vitro susceptibility profile of ceftobiprole against MRSA isolates
J. Kuryan, M. Shah, W. Perez, A. Jangi, E. Wu, J. Seedor, D. Ritterband, Depts. of Ophthalmology and Laboratory Medicine, The New York Eye and Ear Infirmary, NY, NY and New York Medical College, Valhalla, NY

Purpose: To compare the in-vitro susceptibility profiles of ceftobiprole (Zeftera/Zevteraä), a novel 5th generation cephalosporin, with 4th generation topical fluoroquinolones against ocular isolates of Methicillin-Resistant Staphylococcus aureus (MRSA).
Methods: 15 MRSA, 3 Methicillin-Sensitive S. aureus (MSSA), 3 Staphylcoccus epidermidis and 1 Streptococcus viridans group isolates from cases of corneal ulcers were tested for in vitro susceptibility against ceftobiprole and two fourth-generation fluoroquinolones, moxifloxacin and gatifloxacin. Susceptibilities were evaluated by a Kirby Bauer method.
Results: Ceftobiprole was active against all 15 MRSA strains tested with zones of inhibition (ZI) ranging from 18 to 38 mm. It was also active against all other Gram positive isolates tested (ZI ranging from 30 to 38 mm). Moxifloxacin and Gatifloxacin had 8/15 resistant and 10/15 resistant MRSA strains, respectively. All 15 MRSA strains were sensitive to vancomycin.
Conclusions: Ceftobiprole is the first of a new class of broad-spectrum cephalosporins with activity against MRSA and other Gram positive species. With rising concern of MRSA-resistance against currently available antimicrobials, ceftobiprole appears to be a promising new therapeutic alternative.

Disclosure Code: N

Top of Page